Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Cost of Revenue history
Currency unavailable · from the income statement
No Cost of Revenue data reported for this period type.
Cost of Revenue vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.42M USD | +24.9% | -18.7% | 7.5% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.01M USD | — | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M USD | +7.4% | +307.8% | 5.0% |
| LTM Mar 2026 | $574K USD | +69.3% | +0.2% | — | |
| LTM Mar 2026 | $268K USD | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $82K USD | — | — | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $79K USD | — | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +24.9% | +0.2% | 6.3% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.